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the duration ochemotherapy-induced myelosuppression, where it has been shown to reduce the duration of severe neutropenia, the duraIntroduction tion of antibiotic therapy, and the length of hospitalization. 7 The pegylated form of G-CSF (peg-G-CSF) has a longer half-life and ulfur mustard (HD) is best known for its effects on epithelial more sustained duration of action than G-CSF.8 Both CSFs are dos tissues of the skin, eyes, or lungs. However, much of the HD Food and Drug Administration (FDA)-approved hematopoietic dose passes into the circulatory system, resulting in systemic growth factors used clinically to treat chemotherapy-induced toxicity.) Included in the systemic targets are bone marrOW and neutropenia. 9 -' 2 In a cooperative study with Amngen (Thousand the lymphatic system. Decreases in white blood cell counts were Oaks, California), Navy researchers Meisenberg et al.mgn showed noted for casualties exposed to mustard during the Iran-Iraq that G-CSF significantly reduced the duration of nitrogen muswar.
2 " 3 The bone marrow injury consists of complete depletion of tard-inducedne nian r hesusamonkeys.iHowev ths the granulocytic sites and degenerative changes in megakaryo-tard-induced neutropenia in rhesus monkeys. However, this cytes, culminating in aplasia. Leukopenia, an abnormal reduc-treatment compound has not been tested specifically against tion in circulating white blood cells (primarily lymphocytes and the chemical warfare compound HD. There is evidence in the neutrophils), may result from bone marrow suppression or from literature of differences in the biological effects and therapeutic recruitment of leukocytes from the bloodstream to sites of sec-efficacies of treatment compounds, with respect to nitrogen ondary infections (margination). HD-induced injury to the lym-mustard and HD. Pechura and Rail 4 stated that, although hematopoietic depression is observed with HD, its degree and *Pharmacology Division, U.S. Army Medical Research Institute of Chemical De-frequency are less than with nitrogen mustard. They attributed fense, Aberdeen Proving Ground, MD 21010-5400. this to a more-direct effect of nitrogen mustard on bone marrow +Research Operations Division. U.S. Army Medical Research Institute of Chemical when given systemically. In comparing HD and two nitrogen Defense, Aberdeen Proving Ground. MD 21010-5400. tComparative Medicine Division. U.S. Army Medical Research Institute of Chemi-mustards, Kindred ' 5 noted that all three compounds tested incal Defense. Aberdeen Proving Ground, MD 21010-5400. duced neutropenia and lymphocytopenia. However, the timing §Chemical Casualty Care Division, U.S. Army Medical Research Institute of Chem-and extent of these changes differed among the three mustards.
ical Defense, Aberdeen Proving Ground, MD 21010-5400.
Portions of this article were presented at the Army Science Conference, December Rappeneau et al.' 6 tested a variety of compounds against both exposed thymocytes than HD-exposed thymocytes. For these reasons, we thought it would be worthwhile to investigate the concentration of 9.5 mg/mL. Immediately before the intraveefficacy of G-CSF for treatment of HD-induced myelosuppresnous injection, the HD was diluted in saline solution to the sion.
appropriate concentration and injected at 1.0 mL/kg. The HD Presented here are data on the hematological profile of HD was administered as two half-dose injections, each infllsed over exposure, with or without G-CSF or peg-G-CSF treatment, for 2.5 minutes with a microprocessor-controlled infllsion pump up to 30 days after exposure, to determine the efficacy of these (model 200P; Stoelting, Wood Dale, Illinois) . The half-time for compounds in ameliorating HD-induced neutropenia. The adhydrolysis of HD in saline solution at room temperature is 30.3 vantage to the Army of testing FDA-approved drugs is much minutes: therefore, each injection was made from a fresh dflufaster fielding and deployment of the products should they prove tion. The average time from start of dilution to completion of HD effective. If neutrophil counts can be returned to control levels injection was 6 minutes. Each mustard injection was followed sooner, then secondary infections may be reduced. This could by a 1.0-mL saline flush. ultimately decrease the duration of antibiotic therapy for soldiers with secondary infections and the length of patient hospi-I-ID Ranging Study talization.
The initial HD exposures were to establish a HD dose thai reproducibly induced significant neutropenia (absolute neutroMethods phil counts l•'•lCsl of <1,000 cells per/.iLl for ->5 days). Nine monkeys {n = 3 per dose) were treated intravenously with one of drawn from the saphenous vein into ethylenediaminetetraacetic days. The dose and the dosing frequency selected were recomacid-treated tubes and mixed. Samples were then analyzed for mended by Amgen and were in the range of those recommended complete blood count and cell differential count with a Cell Dyne for use as a chemotherapy adjunct. G-CSF therapy was initiated 3500 hematology analyzer (Abbott Diagnostics, Santa Clara, 1, 3, 5, or 7 days after exposure (n = 4-7 per group). Parallel California).
HD-only and G-CSF-only control groups (rl = 6) were also included. A single close of HD (1.0 mg/kg, administered intrave-HD Exposure nously) was used for exposure. Table I shows the timing of liD Animals were anesthetized with ketamine (15 mg/kg, admin-administration in relation to the beginning of G-CSF treatment. istered intramuscularly) and weighed; a 22-guage catheter was Blood samples were collected from animals receiving both lid introduced into the saphenous vein for HD administration. HD and G-CSF immediately before and 1.3, 5, and 7 days after (purity, >97%) was obtained from the Edgewood Chemical Bio-exposure (depending on the G-CSF group) and periodically logical Center (Aberdeen Proving Ground, Maryland). The HD thereafter for 30 days after G-CSF treatment initiation. Blood working stock solution was made up in absolute ethanol, at a samples were collected from HD control and G-CSF control 
HD indicates day of dosing with sulfur mustard: G-CSF. daily G-CSF injections initiated; x. blood sample drawn. All G-CSF dosing l×'gan on day 0. The arrows on the right indicate that daily G-CSF dosing and blood sampling continued, as described in the text. The sample size tot each group is given in parentheses.
animals immediately before HD or G-CSF administration and A periodically thereafter for 30 days. One-factor analysis of variance was used, followed by Tukey's multiple-comparison test if significant treatment group or study 0o.1 day differences were observed. All statistical tests were conducted at the a = 0.05 level. Animals were challenged with 1.0 mg/kg HD, administered (C Data for 1.5 mg/kg HD, administered intravenously. WBC, total white blood cell count; Lymph, lymphocytes. The horizontal dashed lines denote our neutropenia intravenously, and G-CSF treatment was initiated 1, 3, 5, or 7 criterion for dose selection (< 1,000 cells per ,gL).
days after exposure. In Figure 2 , the ANC values for the four treatment groups, relative to the two control groups (HD only recovered 8 to 19 days after exposure (Fig. 2) . The duration of and G-CSF only), are shown. Table II shows that the ANC nadir neutropenia and severe neutropenia (i.e., the number of days was typically reached 5 to 9 days after exposure. The nadir for with ANC of < 1,000 cells per AL or <500 cells per tLL, respecanimals receiving G-CSF beginning at I day (372 cells per 1L) tively) for each treatment group is shown in Table II . G-CSF was observed on day 5. It can be seen in Table II that, the longer treatment significantly (p < 0.05) shortened the duration of treatment was delayed, the lower was the nadir. All G-CSF neutropenia, relative to untreated animals. treatment groups recovered from HD-induced neutropenia faster than did the untreated control animals (HD only). Un-Pegylated G-CSF Evaluation treated animals did not recover from HD-induced neutropenia In this experiment, peg-G-CSF was administered subcutaneuntil day 28 after exposure, whereas the G-CSF-treated animals ously once at a dose of 300 /g/kg, on day 3 after exposure (o = t cly c s Ot-H thought this critical study was justified. In addition, we evalu- mg/kg dose was selected for use in the G-CSF evaluation. In comparison with the rhesus monkeys in the study by Meisen-6). Control groups (HD only and HD/G-CSF: n = 3) were also berg et al.1
3 with nitrogen mustard, the AGMs used in the curstudied, and these data were pooled with the previous data. The rent study had a longer period of neutropenia 123.5 days for ANC for peg-G-CSF-treated animals responded very rapidly to untreated HD-exposed animals vs. 6.3 days for rhesus montreatment but dropped to a nadir at 7 days after exposure (Fig. keys) . Unfortunately, it is not possible to determine whether this 3). It is noteworthy that the mean ANC nadir was higher for the is a species difference, a result of the different mustards used, or peg-G-CSF-treated animals (704 cells per AL) than for the G-a combination of these two factors. CSF day 3 group (358 cells per AL) and HD-only animals (143
In the main portion of the study, we wanted to determine cells per .L) (Table II and Fig. 3) . The mean ANC then increased whether G-CSF would alleviate HD-induced neutropenia, as above the 1,000 cells per jL neutropenia level on day 10 but well as how long the treatment could be delayed and still mainfluctuated around that level through day 28. Although the cor-tain efficacy. It can be seen in Figure 2 that G-CSF effectively responding G-CSF-treated animals did not recover from neutro-alleviated HD-induced neutropenia. All of the four treatment penia until day 12, the ANC for those animals continued to groups recovered from neutropenia faster than did the HD-only increase for the duration of treatment (Fig. 3) .
control group and returned to baseline ANC levels faster than did the untreated control animals. However, it is not possible to Other Hematological Parameters statistically discriminate among any of the four treatment deFigures 4, 5, and 6 show the effects of HD exposure on lym-lays (1, 3, 5, or 7 days). The 7-day animals had effectively phocyte counts, red blood cell (RBC) counts, and platelet reached their ANC nadir when treatment began, and these ancounts, respectively. All of the G-CSF treatment groups were imals immediately began to recover from neutropenia after pooled in these figures. Lymphocytes were the most rapidly treatment initiation. The ANC nadir for each of the other groups affected (Fig. 4) , showing a dramatic decrease within 1 day after was reached after G-CSF treatment was initiated, but recovery HD exposure and reaching a nadir 3 to 5 days after exposure. from neutropenia for each group was faster than that for unThe pronounced fluctuations in the HD/G-CSF data in the first treated animals. These results were comparable to the observadays after HD were attributable to the lymphocyte responses to tions of Meisenberg et al.' 3 the various treatment delays. RBC levels (Fig. 5 ) remained fairly Interestingly, concomitant with a marked decrease (--70%) in constant for 8 to 10 days after exposure, after which they lymphocytes observed 1 day after exposure, there was usually a steadily declined until reaching a low point 17 to 28 days after transient increase in ANC. Despite this initial influx of neultroexposure. The reduction in platelet numbers (Fig. 6 ) was very phils, the ANC began to decrease by day 4, reaching the nadir 5 dramatic and temporally lagged slightly behind the drop in neu-to 9 days after exposure. A second spike in ANC was generally trophils. HD induced severe thrombocytopenia (-90% decrease) observed -I day after the start of G-CSF administration. This 9 to 11 days after exposure for all exposure groups. Platelet rapid post-G-CSF spike is thought to be attributable to the counts returned to baseline levels by 16 to 19 days after expo-release of reserve neutrophils/precursors from the bone marrow sure.
(left shift). After reaching a nadir 5 to 9 days after exposure, the G-CSF-treated animals recovered significantly faster from neuDiscussion tropenia than did their untreated cohorts. The group with the shortest duration of neutropenia, the day I group (ANC of The primary goal of this study was to validate the recommen-< 1,000 for 6.2 days) ( Table II) , was treated at the time recomdation by Meisenberg et al." for the use of G-CSF against HD-mended by the American Society of Clinical Oncology for G-CSF induced neutropenia. Their recommendation was based on a used as a chemotherapy adjunct. 11 In a military setting, it may study using only nitrogen mustard. Because there have been not be possible to initiate treatment 1 day after exposure: thereseveral examples in the literature of treatment compounds that fore, the other treatment delays were also evaluated. were effective against nitrogen mustard but not HD,1 4 ' horizontal dotted lines denote significant (<1,000 cells per AL) or severe (<500 tered subcutaneously daily for 21 days). The G.CSF-only group was not exposed to cells per gL) neutropenia.
HD.
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H---t-Oonly Day Post HD Exposure Day Post HD Exposure   Fig, 4 . Effect of HD on average lymphocyte counts in AGMs exposed to HD (1.0 Fig. 6 . Effect of HD on average platelet counts in AGMs exposed to HD (1.0 mg/kg. mg/kg. administered Intravenously) on day 0 and treated with G-CSF (10 Mg/kg, administered intravenously) on day 0 and treated with G-CSF (10 Ag/kg, adminisadministered subcutaneously daily for 21 days). The G-CSF-only group was not tered subcutaneously daily for 21 days). The G-CSF-only group was not exposed to exposed to HD.
HD, tion was given 3 days after exposure. This delay interval was selected as a realistic time frame in which a soldier exposed on the American Society of Clinical Oncologists as severe neutroa battlefield could be transported to a medical facility and eval-penia (<500 cells per pL). The peg-G-CSF ameliorated the HDuated and treatment begun. The caveat with this dosing delay is induced neutropenia as fast as or faster than G-CSF, but the that, as with G-CSF, treatment with peg-G-CSF 1 day after effect was not fully maintained. The mean ANC for the peg-Gchemotherapy is the most effective timing for decreasing the CSF-treated group fluctuated around 1,000 cells per /L from severity and duration of neutropenia.' 9 Treatment with peg-G-day 10 through day 21 after HD (Fig. 3) . With pegylation of the CSF 3 days after HD resulted in a mean ANC nadir (702 cells per molecule, renal clearance is minimized and neutrophil-medi-AL) that was not nearly as severe as that seen in the HD-only ated endocytosis is the predominant route of elimination, which group (143 cells per QL) or with daily G-CSF treatment (254-372 gives peg-G-CSF a much longer circulating half-life than G-CSF. cells per QL) (Table II) . This is a significant benefit over the Therefore, the biological effect of peg-G-CSF is prolonged in a standard G-CSF therapy, because the mean ANC for the peg-Gneutropenic condition, and the drug is slowly eliminated as CSF-treated animals never dropped to the level characterized by neutrophil numbers increase.
8 This self-regulating design of peg-G-CSF may be providing a sufficient number of neutrophils In conclusion, these results indicate that both G-CSF and 20. tMivcenski JW. Sliogari JE: Maximiizinig the ourtcomres fii cancer piatrirnts recrivirng peg-G-CSF may provide a FDA-approved treatment that can cherrothierapy through optirrial rise-of cotorry-stirriiititirg factor. .1 Maniage ('arc reduce the duration of HD-induced neutropenia. Treatment 
